Pharmacological management of bronchial asthma focusing on biological treatment
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.contributor.author | Yoshikawa, Takahide | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | |
| dc.contributor.opponent | Megyeri, Attila | |
| dc.contributor.opponent | Halasi, Barbara | |
| dc.contributor.opponentdept | Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.contributor.opponentdept | Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet | |
| dc.date.accessioned | 2026-04-15T09:51:15Z | |
| dc.date.available | 2026-04-15T09:51:15Z | |
| dc.date.created | 2025-11-18 | |
| dc.description.abstract | Bronchial asthma is a chronic inflammatory airway disease characterized by variable symptoms and reversible airflow limitation. In recent years, biologic therapies have emerged as an important treatment option, particularly for patients with severe or therapy-resistant asthma. The aim of this thesis was to review current pharmacological treatment strategies for asthma, with a focus on the clinical role and effectiveness of biologic therapy. The review was based on international clinical guidelines and recent randomized controlled trials published between 2018 and 2025. Biologic agents targeting IgE, IL-5, IL-4 receptor, and TSLP have shown significant reductions in exacerbation rates, oral corticosteroid dependence, and symptom burden in selected patient populations. Treatment response appears to correlate with biomarkers such as blood eosinophil count, IgE levels, and fractional exhaled nitric oxide (FeNO). In conclusion, biologic therapy represents a major advancement in asthma management. Appropriate patient selection and a biomarker-guided approach are key to achieving optimal outcomes. | |
| dc.description.course | általános orvos | |
| dc.description.courselang | angol | |
| dc.description.degree | egységes, osztatlan | |
| dc.format.extent | 43 | |
| dc.identifier.uri | https://hdl.handle.net/2437/406247 | |
| dc.language.iso | en | |
| dc.rights.info | Hozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében. | |
| dc.subject | asthma, biologics, bronchial asthma | |
| dc.subject.dspace | Medicine | |
| dc.title | Pharmacological management of bronchial asthma focusing on biological treatment |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- THESIS Takahide Yoshikawa FINAL.pdf
- Méret:
- 750.59 KB
- Formátum:
- Adobe Portable Document Format
- Leírás:
Engedélyek köteg
1 - 1 (Összesen 1)
Nincs kép
- Név:
- license.txt
- Méret:
- 1.94 KB
- Formátum:
- Item-specific license agreed upon to submission
- Leírás: